

Report on antimalarial drug efficacy, resistance and response




years of surveillance (2010–2019)





Report on antimalarial drug efficacy, resistance and response



years of surveillance (2010-2019)



Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019)

ISBN 978-92-4-001281-3 (electronic version) ISBN 978-92-4-001282-0 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/)

Suggested citation. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: World Health Organization: 2020. Licence: CC RY-NC-SA 3.0 IGO

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout by Lushomo, South Africa

Contents

Acknowled	gemen	its	•
Abbreviati	ons and	d acronyms	v
Executive	summa	ry	vi
1. Introduc	tion		
2. Antimal	arial tre	eatment	
2.1	WHO-	recommended treatments for malaria	
2.2	Other	recommended use of antimalarial medicine	2
3. Antimal	arial dr	rug resistance	
3.1	Defining antimalarial drug resistance		
3.2	Artemisinin partial resistance		2
3.3	Global public health implications of antimalarial drug resistance		Į
3.4	Responding to the global threat of resistance		
4. Tools for	monite	oring antimalarial drug efficacy and drug resistance	Ç
4.1	Thera	peutic efficacy studies	Ç
	4.1.1	TES for <i>P. falciparum</i>	Ç
	4.1.2	Classification of recurrent <i>P. falciparum</i> infections	12
	4.1.3	P. falciparum TES in different settings	12
	4.1.4	TES for P. vivax and P. ovale	13
	4.1.5	Frequent deviations from the WHO TES standard protocol	17
4.2	Integr	ated drug efficacy surveillance	18
4.3	Evalud	ating the cause of treatment failure	19
	4.3.1	Studies of drug blood levels	19
	4.3.2	In vitro and ex vivo tests	19
	4.3.3	Molecular markers	2
4.4	Inform	ning policy change	24

5. Data on	antimalarial drug efficacy and drug resistance (2010–2019)	25	
5.1	Summary		
5.2	WHO African Region	27	
	5.2.1 WHO African Region: Central Africa	27	
	5.2.2 WHO African Region: Eastern and Southern Africa	29	
	5.2.3 WHO African Region: West Africa	30	
5.3	WHO Region of the Americas	32	
5.4	WHO South–East Asia Region	34	
5.5	WHO Eastern Mediterranean Region	37	
5.6	WHO Western Pacific Region	39	
5.7	Other species		
References	S Company of the comp	44	
Annex 1:	Countries where <i>Plasmodium vivax</i> chloroquine failure or resistance was reported		
Annex 2:	Summary of treatment failure rates grouped by species, treatment, country and WHO region	52	
Annex 3:	Countries by WHO regions and inter-country support teams	63	

ACKNOWLEDGEMENTS

This document was prepared for the World Health Organization (WHO) Global Malaria Programme (GMP) by Charlotte Rasmussen and Pascal Ringwald, with the support of Amy Barrette and Lucia Fernandez Montoya (for the management of the database and the threats maps). WHO/GMP wishes to thank Kevin Baird, Leonardo Kishi Basco, Maria Dorina Bustos, Laurence Slutsker and Mariam Warsame for their deep review of the document and helpful suggestions. WHO/GMP also acknowledges the comments made by the regional advisors and colleagues from the regions: Elisabeth Juma, Akpaka Kalu, James Kelly, Roberto Montoya, Spes Caritas Ntabangana, Risintha Gayan Premaratne, Abderahmane Kharchi Tfeil, Maria de la Paz Ade y Torrent, Neena Nee Kesar Valecha and Ghasem Zamani. WHO/GMP wishes to thank the ministries of health, nongovernmental organizations, pharmaceutical companies, public private partnerships, research institutes, collaboratives centres, subregional networks and WHO regional offices that kindly shared their data. Financial support for the preparation of this document and the database was provided by the Bill & Melinda Gates Foundation. The final draft was edited by Cadman Editing Services, Australia.

ABBREVIATIONS AND ACRONYMS

ACPR adequate clinical and parasitological response

ACT artemisinin-based combination therapy

AL artemether-lumefantrine

AQ amodiaquine AS artesunate

AUC area under the plasma drug concentration curve

CQ chloroquine
DHA dihydroartemisinin
ETF early treatment failure

G6PD glucose-6-phosphate dehydrogenase

GMP Global Malaria Programme
GMS Greater Mekong subregion

GPARC Global Plan for Artemisinin Resistance Containment

HIV human immunodeficiency virusiDES integrated drug efficacy surveillanceIPTi intermittent preventive treatment of infants

IPTp intermittent preventive treatment of pregnant women

LCF late clinical failure

LPF late parasitological failure MDA mass drug administration

MQ mefloquine

PCR polymerase chain reaction

Pfcrt P. falciparum chloroquine resistance transporter

Pfcytb P. falciparum cytochrome b

Pfdhfr P. falciparum dihydrofolate reductase **Pfdhps** P. falciparum dihydropteroate synthase

PfK13 P. falciparum Kelch 13

Pfmdr1 P. falciparum multidrug resistance 1 protein

Pfpm 2-3 P. falciparum plasmepsin 2-3

PPQ piperaquinePQ primaquine

Pvcrt-o P. vivax chloroquine resistance transporter

Pvdhfr
 Pvdhps
 Pvivax dihydrofolate reductase
 Pvivax dihydropteroate synthase
 Pvmdr1
 Pvivax multidrug resistance 1 protein

PSA piperaquine survival assay

PY pyronaridine

RSA ring-stage survival assay

SMC seasonal malaria chemoprevention

SP sulfadoxine-pyrimethamine

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5 24255



